Gabriela Plesa

5 ta ish

University of Pennsylvania

1. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

   Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai +18

   MaqolaOAOchiq kirish20174 iqtibos

   ABIABI:AkademIndex/2026.other.020482

2. CRISPR-engineered T cells in patients with refractory cancer

   Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis +38

   MaqolaOAOchiq kirish20203 iqtibos

   ABIABI:AkademIndex/2026.other.102870

3. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

   Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus +9

   MaqolaOAOchiq kirish20132 iqtibos

   ABIABI:AkademIndex/2026.other.082777

4. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

   Sangya Agarwal, M. Ángela Aznar, Andrew J. Rech +17

   MaqolaOAOchiq kirish20232 iqtibos

   ABIABI:AkademIndex/2026.other.102947

5. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results

   Stephen Bagley, Meghan Logun, Joseph A. Fraietta +30

   MaqolaOAOchiq kirish20242 iqtibos

   ABIABI:AkademIndex/2026.other.102963